Assembly Biosciences Inc (ASMB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$36.60+1.30%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ASMB
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Progress ABI-6250 clinical development with Phase 2 studies in hepatitis delta virus and expansion into cholestatic liver diseases.
Stated as a priority in 2 of last 2 quarters. ABI-6250 clinical development advanced with Phase 2 initiation expected in Q4 2026 for HDV and expansion into cholestatic liver diseases with Phase 2 anticipated in Q1 2027. The trajectory is delivering with clear milestone timing and program expansion.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Expanded ABI-6250 clinical development into cholestatic liver diseases, including PBC and PSC, with Phase 2 study anticipated in Q1 2027.”
“Completed chronic toxicology studies for ABI-6250; Phase 2 initiation anticipated Q4 2026.”
Assess whether to opt in to 40% U.S. cost and profit share for herpesvirus helicase-primase inhibitor program with Gilead.
Stated as a priority in 2 of last 2 quarters. Management reiterated evaluation of the opt-in decision for the herpesvirus program with Gilead, targeting year-end 2026 after receiving commercial cost estimates. The priority remains active with progress toward decision timing.
“Expect to make determination on opt-in to 40% U.S. cost-profit share soon after receiving Gilead's commercial cost estimates.”
“Will evaluate cost and profit share opt-in decision for herpesvirus program by mid-2026 upon receipt of Gilead's development plan and budget.”
Preserve financial resources to support operations through 2029, including recent financing and collaboration extension payments.
Stated as a priority in 3 of last 3 quarters. Cash and equivalents increased from $226.6 million in 2026-Q1 to $320.4 million in 2026-Q2, supported by a $115 million financing and Gilead collaboration extension payment. The cash runway projection extended from 2028 to 2029, indicating delivering trajectory on financial resource preservation.
“Cash position projected to fund operations into 2029, including $75 million Gilead extension payment due Q4 2026.”
“Cash position projected to fund operations into 2028.”
“Cash, cash equivalents and marketable securities were $248.1 million as of December 31, 2025.”
Continue development of herpesvirus helicase-primase inhibitors ABI-5366 and ABI-1179 under collaboration with Gilead.
Stated as a priority in 2 of last 2 quarters. Clinical development progressed with completion of Phase 1b studies for ABI-5366 and ABI-1179, and Gilead's selection of GS-1179 for Phase 2 initiation by end 2026. The trajectory shows delivering progress in advancing these programs.
“GS-1179 selected to advance in HSV HPI program with Phase 2 initiation expected by year-end 2026.”
“Completed Phase 1b studies for ABI-5366 and ABI-1179, reinforcing confidence in safety and efficacy.”
Oversee leadership changes and roll out the 2026 Corporate Bonus Plan to align employee incentives.
Stated as a priority in 2 of last 2 quarters. Management reported officer changes and implementation of a new 2026 Corporate Bonus Plan. These disclosures indicate ongoing focus on talent management and incentive alignment with limited quantitative financial impact.
“Filing pertains to stockholder-approved amendments to the company's incentive plans.”
“Filing describes a new cash bonus plan for employees, not a management change.”
Over the trailing year it converted -0.26x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
13 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.